In light of our discoveries, we propose that usenamine A holds significant promise as a prospective pharmaceutical agent for the management of HCC featuring aberrant AKT/mTOR/STAT3/ID1 signaling. The gene discussed is STAT3; the disease is hepatocellular carcinoma.